UK markets close in 23 minutes

Eagle Pharmaceuticals, Inc. (EGRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.9600+0.0100 (+0.25%)
As of 10:59AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 51.18M
Enterprise value 107.45M
Trailing P/E 4.65
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.20
Price/book (mrq)0.20
Enterprise value/revenue 0.42
Enterprise value/EBITDA 1.92

Trading information

Stock price history

Beta (5Y monthly) 0.46
52-week change 3-80.16%
S&P500 52-week change 325.22%
52-week high 323.5200
52-week low 33.2100
50-day moving average 34.2429
200-day moving average 37.6014

Share statistics

Avg vol (3-month) 3148.03k
Avg vol (10-day) 3114.23k
Shares outstanding 512.96M
Implied shares outstanding 612.99M
Float 89M
% held by insiders 112.02%
% held by institutions 181.63%
Shares short (15 May 2024) 41.14M
Short ratio (15 May 2024) 48.64
Short % of float (15 May 2024) 413.62%
Short % of shares outstanding (15 May 2024) 48.79%
Shares short (prior month 15 Apr 2024) 41.18M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 4.64%
Operating margin (ttm)15.94%

Management effectiveness

Return on assets (ttm)6.63%
Return on equity (ttm)4.88%

Income statement

Revenue (ttm)257.55M
Revenue per share (ttm)19.68
Quarterly revenue growth (yoy)-12.80%
Gross profit (ttm)N/A
EBITDA 62.33M
Net income avi to common (ttm)11.95M
Diluted EPS (ttm)0.8500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)15.35M
Total cash per share (mrq)1.18
Total debt (mrq)72.45M
Total debt/equity (mrq)28.75%
Current ratio (mrq)2.16
Book value per share (mrq)19.25

Cash flow statement

Operating cash flow (ttm)-9.32M
Levered free cash flow (ttm)38.31M